Arcus Biosciences
RCUS
231 hedge funds and large institutions have $3.78B invested in Arcus Biosciences in 2026 Q2 according to their latest regulatory filings, with 47 funds opening new positions, 87 increasing their positions, 63 reducing their positions, and 24 closing their positions.
495% more call options, than puts
Call options by funds: $15.6M | Put options by funds: $2.62M
96% more first-time investments, than exits
New positions opened: 47 | Existing positions closed: 24
47% more capital invested
Capital invested by funds: $2.57B → $3.78B (+$1.21B)
38% more repeat investments, than reductions
Existing positions increased: 87 | Existing positions reduced: 63
20% more funds holding in top 10
Funds holding in top 10: 5 → 6 (+1)
9% more funds holding
Funds holding: 211 → 231 (+20)
2.52% more ownership
Funds ownership: 95.02% → 97.54% (+2.5%)
Top Buyers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Fidelity Investments
Boston,
Massachusetts
|
+$71.3M |
| 2 |
Citadel Advisors
Miami,
Florida
|
+$44.6M |
| 3 |
BlackRock
New York
|
+$29.4M |
| 4 |
SCM
Soleus Capital Management
Greenwich,
Connecticut
|
+$17.7M |
| 5 |
State Street
Boston,
Massachusetts
|
+$15.2M |
Top Sellers
| Rank | Fund | Capital Flow |
|---|---|---|
| 1 |
Marshall Wace
London,
United Kingdom
|
-$44.9M |
| 2 |
TECP
Trails Edge Capital Partners
Atlanta,
Georgia
|
-$22.6M |
| 3 |
WP
Woodline Partners
San Francisco,
California
|
-$19M |
| 4 |
SL
Siren LLC
Greenwich,
Connecticut
|
-$14.5M |
| 5 |
LGM
Logos Global Management
San Francisco,
California
|
-$13.6M |
RCUS Hedge Fund Activity: Q2 2026 in Review
231 of the 8,317 institutional investors tracked by Wall St. Rank reported a position in Arcus Biosciences (RCUS) for Q2 2026, worth a combined $3.78B — up 47% from $2.57B a quarter earlier.
Buyers outnumbered sellers: 47 funds opened new RCUS positions and 24 closed out — a net gain of 23 holders — while 87 added to existing stakes and 63 trimmed.
The largest buyer was Fidelity Investments, adding an estimated $71.3M. The largest seller was Marshall Wace, cutting an estimated $44.9M.
- 231 institutional investors held Arcus Biosciences (RCUS) as of Q2 2026, up from 211 in Q1 2026.
- Funds reported $3.78B of Arcus Biosciences stock for Q2 2026, up 47% quarter-over-quarter.
- 47 funds opened new Arcus Biosciences positions in Q2 2026 and 24 closed out, a net change of +23 holders.
- The largest Arcus Biosciences buyer in Q2 2026 was Fidelity Investments, an estimated $71.3M added.
- The largest Arcus Biosciences seller in Q2 2026 was Marshall Wace, an estimated $44.9M sold.
Based on aggregated 13F filings for Q2 2026.